What Captimer Treats: Main Uses and Benefits

Captimer (Generic name: Trazodone) is a medication applied in addressing Major Depressive Disorder (MDD) in adults, and its use is considered relevant for easing symptoms associated with this condition. The medication is applied across domains where additional symptomatic support is needed.

The therapeutic context of Captimer is often used during phases when symptoms become more noticeable. It is relevant for easing symptoms that interfere with daily comfort, such as those impacting sleep, mood, appetite, and energy level. The medication is commonly used to help with symptom clusters that may become intense or disruptive. Applied in scenarios where additional management of discomfort is required, Captimer supports patients during difficult episodes by easing distress and assists with maintaining functional stability, which may assist with easing the overall symptom burden during periods of heightened symptoms.

---

Quick Fact: Focus on Symptoms that Interfere with Daily Functioning

Regulatory References

1. NIH MedlinePlus overview of Trazodone

Who Can and Cannot Use Captimer?

This section outlines the official population eligibility and non-eligibility for Captimer (Tiopronin) as defined by government regulatory agencies.

Populations Excluded from Use

Classification	Rule
Absolute Contraindication	Patients with known hypersensitivity to tiopronin or any component of the formulation must not use Captimer.
Mandatory Discontinuation	Use must be stopped if a patient develops proteinuria (including nephrotic syndrome) during treatment.

---

Age and Physiological Restrictions

• Pediatric Eligibility: Captimer is approved for pediatric patients with severe homozygous cystinuria who weigh 20 kg and greater. Safety and efficacy are not established for children weighing less than 20 kg.
• Geriatric Use: Special caution and monitoring of renal function may be required for older adults due to the higher likelihood of reduced kidney function.
• Pregnancy and Lactation: Breastfeeding is not recommended due to the potential for serious adverse reactions in the infant; however, available data have not identified a drug-associated risk for major birth defects during pregnancy.

Interactions with other medicines and products

This section details the formal interaction patterns and constraints documented in official regulatory sources for Captimer (Tiopronin).

Interaction Scope

Medicinal product categories with documented interactions: Alcohol (Ethanol) is the primary substance category with a specific pharmacokinetic interaction. Food is noted for the immediate-release formulation, which requires administration spacing.

Mechanistic basis of interactions: The co-administration of Alcohol (Ethanol) is documented to cause an increased release rate of tiopronin from the delayed-release tablet, leading to altered drug exposure. No known Cytochrome P450 (CYP) enzyme or general metabolic interactions are explicitly stated in the primary regulatory labeling.

Timing-based interaction rules: For the delayed-release tablet, consumption of alcohol must be avoided 2 hours before and 3 hours after taking the medication. While the delayed-release form has no required timing separation with food, the immediate-release formulation must be administered at least one hour before or two hours after meals.

Population-specific interaction notes: Due to the drug being substantially excreted by the kidney, older adult patients may have an increased risk of adverse reactions because age-related reduction in renal function can slow the drug's clearance.

Interaction Classifications (High-Level)

Interaction-related restrictions: Captimer is formally contraindicated in patients with known hypersensitivity to tiopronin or any of its excipients. The interaction with alcohol necessitates a mandatory timing restriction to manage the exposure modification risk.

Connection to the overall interaction profile: The drug’s official interaction profile is chiefly defined by a specific pharmacokinetic restriction with alcohol that requires strict timing separation to prevent undesirable exposure changes. Beyond this, the profile includes formal contraindications and population-specific cautions related to the drug’s renal elimination pathway.

Chemical Modification and Systemic Clearance

The action of Captimer (Tiopronin) is achieved through direct chemical mechanisms, distinct from typical receptor-mediated processes. Its core function begins with the active sulfhydryl group ( -SH) engaging in thiol-disulfide exchange , a reaction that targets disulfide bonds ( R-S-S-R'). This chemical transformation results in the formation of a highly soluble mixed disulfide complex.

This molecular change is critical for modulating the urinary excretion pathway. The resulting complexes exhibit reduced potential for precipitation in solution due to their increased water solubility. This facilitates the removal of the modified substances from the system, influencing their circulating concentration.

Furthermore, the Tiopronin molecule contributes to modulation of the cellular redox environment. It acts as a free radical scavenger and neutralizes Reactive Oxygen Species (ROS), thereby influencing the cellular redox status. Its structure also allows for chelation, forming stable complexes with certain heavy metal ions to facilitate their systemic removal.

Captimer, containing Tiopronin, is administered orally in the form of tablets as part of a long-term therapeutic protocol. The drug is classified as an adjunctive therapy, meaning it is used in combination with high fluid intake, alkali agents, and diet modification.

Standard Dosing and Administration Schedule

The total daily dosage is administered in three equally divided doses, which should be taken at the same times each day. For adults, the typical initial daily dose is 800 mg. This dosage is not fixed, but is individually titrated (adjusted) based on therapeutic monitoring to achieve the required urinary cystine concentration below 250 mg/L. This concentration is verified by measuring urinary cystine 1 month after starting treatment and every 3 months thereafter.

The timing relative to meals varies by formulation:

• Immediate-Release (IR) tablets must be taken on an empty stomach, specifically at least one hour before or two hours after meals.
• Delayed-Release (EC) tablets may be taken with or without food. These tablets must be swallowed whole to maintain their release mechanism.

Age-Group Rules and Special Handling

For pediatric patients ge 9 years old or ge 20 kg, the initial daily dose is determined by weight, starting at 15 mg per kilogram per day. It is required that dosages greater than 50 mg/kg per day must be avoided. If a patient is unable to swallow the Delayed-Release tablet whole, the tablet may be crushed and mixed with approximately 1 tablespoon of applesauce, provided the mixture is consumed immediately or within two hours.

Research evidence / Overview of studies for Captimer

Evidence for use in Preventing Cystine Stone Formation

Clinical evidence for Captimer includes retrospective and prospective observational cohorts, along with long-term uncontrolled trials. Research examined how outcomes related to cystine excretion and stone formation rates were monitored. The collected data show patterns related to urinary cystine levels in observed populations. These studies contribute to the broader evidence landscape for managing systemic imbalance in this condition.

Comparative Research Landscape

Research has explored Captimer when compared with other medicines studied and with non-drug interventions. Randomized studies were conducted to evaluate differences between these treatment approaches, including patients who had previously used d-penicillamine. However, specific comparative evidence is lacking for many long-term endpoints.

Long-Term Evidence and Durability of Study Findings

Because this is a chronic condition, research explored patterns observed over extended periods, with follow-up extending for multiple years in some trials. This data is supplemented by post-marketing surveillance reports and patient registries. However, there is limited information for long-term outcomes from formal, controlled trials, and long-term outcomes are not fully established.

Evidence in Pediatric and Other Study Populations

Captimer was studied for use in both adults and pediatric patients starting from 20 kg body weight. Research examined specific subgroups, including those with prior d-penicillamine treatment. For certain other populations, such as pregnant or breastfeeding individuals, data for certain groups remain insufficient, and subgroup findings are uncertain in these areas.

Identified Gaps and Areas for Future Research

A key limitation noted in regulatory reviews is that formal, long-term studies designed to assess carcinogenicity or mutagenicity have not been performed. The evidence quality varies across studies, with a significant reliance on uncontrolled data for long-term clinical experience, which provides limited insight into specific long-term outcomes.

Common questions about Captimer (FAQ)

---

Q: What is Captimer used for?

A: According to official product information, Captimer is a medicine used to treat chronic myeloid leukemia (CML), which is a type of cancer that affects white blood cells. It is specifically indicated for adult patients who are in the chronic phase, accelerated phase, or blast phase of CML, including newly diagnosed patients and those who have failed previous treatments.

Q: How does Captimer work in the body?

A: Captimer works by blocking the activity of certain proteins, specifically the BCR-ABL tyrosine kinase. This abnormal protein is present in CML cells and is essential for the growth of the cancer. By inhibiting this protein, regulatory documents state that Captimer helps to stop the growth and division of the leukemia cells.

Q: What is the primary goal of treatment with Captimer?

A: The primary goal of treatment, as indicated in official product information, is to achieve a significant reduction in the number of leukemia cells. This is known as a hematologic (blood) or cytogenetic (chromosome-level) response. Studies and official information indicate that successful treatment aims to improve patient outcomes by controlling the cancer.

Q: Can I take Captimer with food?

A: Regulatory documents state that Captimer should be taken with food. Taking the medicine with a meal is important to help the body absorb it correctly. The regulatory information states the tablets should be swallowed whole.

Q: What should I do if I miss a dose of Captimer?

A: Regulatory documents describe specific actions for managing a missed dose, based on the time elapsed since the usual administration. For instance, if it has been less than 12 hours, the missed dose is taken; if longer, it is skipped. Official information cautions against taking a double dose to compensate for a missed one.

Q: How will my doctor monitor my treatment with Captimer?

A: During treatment with Captimer, official product information indicates that a doctor will frequently monitor a patient's progress. This generally includes regular blood tests to check blood cell counts and liver function. Specific tests are also performed to monitor the level of the BCR-ABL protein to assess the treatment's effectiveness.

Q: Is Captimer a form of chemotherapy?

A: Captimer is a form of targeted therapy and is not the same as traditional chemotherapy. According to the official product information, it specifically targets the abnormal protein that drives CML, which means it generally affects healthy cells differently than traditional chemotherapy. This type of medicine is known as a tyrosine kinase inhibitor.

The official requirements for storing and disposing of Captimer (Tiopronin) tablets are based on strict regulatory standards to maintain stability and ensure safety.

Storage Requirements

The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The regulatory labeling permits brief temperature excursions only between 15 C and 30 C. The product must be protected from moisture and kept in the original container with the cap tightly closed to preserve its integrity. All tablets must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Captimer must be disposed of according to local requirements and official guidance. This typically involves following a local drug take-back program. If no such program is available, the product should be disposed of in household trash by mixing it with an unappealing substance and sealing it, following procedures outlined by government health authorities.